|
|
|
|
|||||
|
|
|
Johnson & Johnson (NYSE:JNJ) is included among the 15 Dividend Stocks that Outperform the S&P 500.
Barclays lifted its price target on Johnson & Johnson (NYSE:JNJ) to $197 from $176 on December 2 while maintaining an Equal Weight rating. The firm also refreshed its estimates for the company.
Johnson & Johnson (NYSE:JNJ) continues to benefit from a strong balance sheet, a foundation that has long supported consistent stability and allowed the company to make substantial investments in research and development as well as targeted acquisitions. Its latest move was the purchase of Halda Therapeutics in a $3.05 billion deal aimed at expanding its oncology pipeline. The acquisition gives J&J access to Halda’s platform for developing oral cancer treatments, aligning with its broader focus on cutting-edge therapeutics.
Johnson & Johnson (NYSE:JNJ) remains strategically centered on high-margin, innovation-driven categories within its Innovative Medicine unit, including oncology, immunology, and neuroscience. Its MedTech arm is concentrated on faster-growing markets such as surgical robotics and digital surgery. For the third quarter, J&J posted net sales of $24 billion, a year-over-year increase of 6.8%, while net income surged 91% to $5.2 billion.
Johnson & Johnson (NYSE:JNJ) is a global healthcare company operating across two core segments: Innovative Medicine and MedTech.
While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 High Quality Dividend Stocks for Long-Term Investors and 14 Best Up and Coming Dividend Stocks to Buy.
Disclosure: None.
| 1 hour | |
| 1 hour | |
| 3 hours | |
| 6 hours | |
| 7 hours | |
| 13 hours | |
| Dec-02 | |
| Dec-01 | |
| Dec-01 | |
| Dec-01 | |
| Dec-01 | |
| Dec-01 | |
| Dec-01 | |
| Nov-30 | |
| Nov-30 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite